Retail Diversion of Legal Drugs
Author : United States. General Accounting Office
Publisher :
Page : 60 pages
File Size : 34,88 MB
Release : 1978
Category : Drug abuse
ISBN :
Author : United States. General Accounting Office
Publisher :
Page : 60 pages
File Size : 34,88 MB
Release : 1978
Category : Drug abuse
ISBN :
Author : Institute of Medicine
Publisher : National Academies Press
Page : 377 pages
File Size : 21,8 MB
Release : 2013-06-20
Category : Medical
ISBN : 0309269393
The adulteration and fraudulent manufacture of medicines is an old problem, vastly aggravated by modern manufacturing and trade. In the last decade, impotent antimicrobial drugs have compromised the treatment of many deadly diseases in poor countries. More recently, negligent production at a Massachusetts compounding pharmacy sickened hundreds of Americans. While the national drugs regulatory authority (hereafter, the regulatory authority) is responsible for the safety of a country's drug supply, no single country can entirely guarantee this today. The once common use of the term counterfeit to describe any drug that is not what it claims to be is at the heart of the argument. In a narrow, legal sense a counterfeit drug is one that infringes on a registered trademark. The lay meaning is much broader, including any drug made with intentional deceit. Some generic drug companies and civil society groups object to calling bad medicines counterfeit, seeing it as the deliberate conflation of public health and intellectual property concerns. Countering the Problem of Falsified and Substandard Drugs accepts the narrow meaning of counterfeit, and, because the nuances of trademark infringement must be dealt with by courts, case by case, the report does not discuss the problem of counterfeit medicines.
Author : National Academies of Sciences, Engineering, and Medicine
Publisher : National Academies Press
Page : 483 pages
File Size : 32,10 MB
Release : 2017-09-28
Category : Medical
ISBN : 0309459575
Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.
Author : United States. Congress. House. Committee on the Judiciary. Subcommittee on Crime
Publisher :
Page : 474 pages
File Size : 27,65 MB
Release : 1985
Category : Drugs
ISBN :
Author :
Publisher :
Page : 356 pages
File Size : 23,71 MB
Release : 1993
Category : Drug traffic
ISBN :
Author : National Academies of Sciences, Engineering, and Medicine
Publisher : National Academies Press
Page : 235 pages
File Size : 27,12 MB
Release : 2018-03-01
Category : Medical
ISBN : 0309468086
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Author : United States. Congress. House. Select Committee on Narcotics Abuse and Control
Publisher :
Page : 98 pages
File Size : 38,15 MB
Release : 1980
Category : Drug abuse
ISBN :
Author : United States. General Accounting Office
Publisher : DIANE Publishing
Page : 63 pages
File Size : 46,59 MB
Release : 2003
Category : Medication abuse
ISBN : 1428942831
Author : National Research Council (U.S.). Committee on Substance Abuse and Habitual Behavior
Publisher : National Academies Press
Page : 55 pages
File Size : 49,86 MB
Release : 1982-01-01
Category : Drug abuse
ISBN :
Defenders of marijuana use may seize on the ambiguity or absence of evidence for such damage and ignore any other effects on education or safety; those opposed to marijuana use may emphasize the possibility of chronic disease that is suggested by some laboratory findings and ignore the social, political, and economic costs of fighting a well-established custom. The Committee wishes to make clear what it regards as the limits of this report for the selection of policy alteratives. Scientific judgment can estimate the prevalence of different kinds of use, risks to health, economic costs, and the like under current policies and can try to project such estimates for new policies. It can come to some conclusions based on those estimates. But selection of an alternative is always a value-governed choice, which can ultimately be made only by the political process.
Author : World Health Organization
Publisher : World Health Organization
Page : 144 pages
File Size : 22,89 MB
Release : 1984
Category : Law
ISBN : 9241541725